35 new projects address MS Australia’s priorities for MS research, including causes and prevention, better treatments and cures via repair and regeneration of cells.
35 new projects address MS Australia’s priorities for MS research, including causes and prevention, better treatments and cures via repair and regeneration of cells.
The goal of the EBV in MS Platform is to better understand the role of EBV in the development of MS and in ongoing disease; and the potential to target EBV to prevent or treat MS
The goal of the EBV in MS Platform is to better understand the role of EBV in the development of MS and in ongoing disease; and the potential to target EBV to prevent or treat MS
“PLATYPUS” - PLatform Adaptive Trial for remYelination and neuroProtection in mUltiple Sclerosis - multi-arm, multi-stage (MAMS) clinical trial which will test two repurposed drugs to help people living with progressive MS.
“PLATYPUS” - PLatform Adaptive Trial for remYelination and neuroProtection in mUltiple Sclerosis - multi-arm, multi-stage (MAMS) clinical trial which will test two repurposed drugs to help people living with progressive MS.
Join us for news and views on the latest research, treatments, and advocacy efforts, as well as candid and informative interviews with our community; those living with MS and their families and carers, together with leading clinicians, researchers, and advocates.
Join us for news and views on the latest research, treatments, and advocacy efforts, as well as candid and informative interviews with our community; those living with MS and their families and carers, together with leading clinicians, researchers, and advocates.
The Neurological Alliance Australia (NAA) is calling for the establishment of a Taskforce for Neurological Conditions, to urgently address the needs of millions of forgotten Australians.
The Neurological Alliance Australia (NAA) is calling for the establishment of a Taskforce for Neurological Conditions, to urgently address the needs of millions of forgotten Australians.
The Pharmaceutical Benefits Advisory Committee (PBAC) will consider adding ocrelizumab (Ocrevus®) via subcutaneous delivery to the PBS for relapsing remitting…
